



## Ycanth Medical Policy


Drug(s) Applied:	Ycanth (cantharidin topical solution 0.7%)
------------------	--

### Criteria:

- I. **Initial Therapy Criteria** - Drug(s) Applied are considered medically necessary when the requested medication meets the criteria below as indicated by chart notes within the past 180 days:
  - A. Diagnosis of molluscum contagiosum confirmed with at least ONE of the following:
    1. Visual assessment by a dermatologist or
    2. Visual assessment by a provider who can make a reasonable conclusion to diagnose molluscum contagiosum (i.e. close family member or caregiver has recently been diagnosed with molluscum contagiosum by a dermatologist **and**
  - B. Patient is 2 years of age or older or prescriber has documented benefit is greater than risk **and**
  - C. Chart notes document quantity and location of lesions and how long they have been present (note: spontaneous resolution can occur in first 6-18 months) **and**
  - D. Patient is not a candidate for non-pharmacologic options (e.g., cryosurgery, curettage) **and**
  - E. If patient is 12 years or older, patient has tried and failed an adequate trial of at least ONE of the following:
    1. Tretinoin cream 0.025% applied with a fine-tipped applicator such as a toothpick for 6-12 weeks
    2. Cimetidine tablets 40 mg/kg/day for 12 weeks **and**
  - F. Patient has tried and failed an adequate trial of Zelsuvmi gel applied daily for 12 weeks

**Approval Units:** up to 2 units  
**Approval Duration:** 3 weeks
- II. **Continued Therapy Criteria** - Drug(s) Applied are considered medically necessary when the requested medication meets the criteria below as indicated by chart notes within the past 120 days:
  - A. Patient meets the initial therapy criteria above **and**
  - B. Last application of Ycanth was more than 3 weeks ago **and**
  - C. Documented positive clinical response to previous Ycanth use

**Approval Units:** up to 4 units  
**Approval Duration:** 6 weeks



Curative considers all other indications as experimental and investigational.

**If submitting for medical billing:**

J7354, cantharidin for topical administration, 0.7% (Ycanth), 1 unit = 1 single-use applicator (3.2mg cantharidin)